Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 24, 1996

View Archived Issues

Fujisawa discloses antiplatelet agents

FDA ophthalmic devices committee meetings scheduled for January

Neuroprotective polypeptide reported by Amgen

Connaught describes potential acellular pertussis vaccines

Bin1 described by Wistar Institute for cancer Rx and Dx

Company Profile: Beacon Diagnostics

Natural antineoplastic agents described by Fujisawa

Otsuka describes new analgesics

Lilly describes potential antirhinoviral compounds

Nonsteroidal 5alpha-reductase inhibitors reported by Kyowa Hakko

One-step HIV test filed with FDA

T Cell Sciences reports progress on TCAR program

Medarex-Houston Biotechnology merger

New Roche joint venture in China

Endorex licenses oral delivery technology

Treatment begun in pivotal trial of Coulter radioimmunopharmaceutical

AACTG begins phase II memantine trial

Novel anti-HIV agent from NCI

Intercardia and Knoll reach agreement for CHF drug

Positive phase III results reported for Ergoset monotherapy

Hyal products for restenosis receive U.S. patent coverage

Copaxone approved by FDA

Agouron files first NDA submission

Novel antihistamine formulation approved by FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.